hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Hyperparathyroidism Signs and Symptoms

Definition

  • Caused by excessive parathyroid hormone (PTH) production

Signs and Symptoms

  • Usually related to elevated levels of PTH & serum calcium
  • Classic signs & symptoms include bone disease, kidney stones & hypercalcinosis
  • Constipation
  • Hypertension
  • Muscle weakness
  • Nausea
  • Polydipsia
  • Polyuria
  • Psychiatric symptoms (depression, anxiety, etc)
  • Significant loss of appetite

Epdemiology

  • Primary hyperparathyroidism is the most common endocrine cause of hypercalcemia in ambulatory patients
  • Occurs more in women than in men aged >50 years old
  • 85-95% of primary hyperparathyroidism is due to adenoma
  • Sporadically arising solitary parathyroid adenoma is the most common primary hyperparathyroidism (PHPT)
  • Familial syndromes - 2nd most common cause of PHPT
  • Renal failure - most common cause of secondary hyperparathyroidism
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.